Biotech BD&L Tracker 2026

A must-add platform BD&L deal and a second Novartis collaboration for Orionis, reinforcing pharma appetite for rational molecular-glue discovery and hard-to-drug target access. The upfront is moderate, but the ~$1.4B milestone stack and repeat-partner signal put it squarely in the tracked 2026 platform-deal set alongside other targeted-protein-degradation and AI-enabled discovery collaborations.

A heavily back-ended but high-signal Alzheimer's BD&L deal that gives Lilly another oral small-molecule approach alongside its anti-amyloid franchise. ACD680 is designed to modulate gamma-secretase biology by reducing harmful Aβ42 production while increasing shorter benign Aβ peptides, giving Lilly optionality around plaque re-accumulation and potentially earlier or preventive Alzheimer's treatment strategies.

A major late-stage targeted-protein-degradation BD&L deal with unusually high upfront cash and meaningful retained economics for Nurix. Roche is buying into a potential best-in-class BTK degrader just ahead of Phase 3, with the strategic angle spanning CLL and other B-cell malignancies plus optionality in immunology and neurology where BTK biology remains highly partnerable.

A useful UK-origin platform BD&L deal in fibrosis, and strategically relevant for GSK's respiratory / immunology / inflammation and hepatology ambitions. The collaboration is not a named clinical-asset license, but it is worth tracking because it targets fibrosis regression — a historically difficult biology — and gives GSK optionality around human-tissue-derived targets rather than conventional preclinical screens.

A notable AI-platform deployment rather than a named therapeutic-asset license. The read-through is that large pharma is moving beyond external AI pilots toward embedded, proprietary-data-trained models that can sit inside biologics discovery workflows and potentially accelerate antibody, multispecific, or hard-target discovery programs.

A smaller regional license, but relevant because it extends Everest's autoimmune-nephrology footprint immediately after the Travere civorebrutinib deal. Bejescin is an anti-CD20 antibody approved in China for primary membranous nephropathy, and the transaction gives Everest APAC commercialization optionality around a de-risked biologic in a specialist kidney-disease market.

A material expansion rather than a brand-new collaboration, but worth tracking because Regeneron is putting additional cash behind conditional bispecific biology and taking the potential value of the CytomX pact to platform scale. It also reinforces renewed strategic interest in masked / conditionally activated oncology biologics as buyers try to widen therapeutic index for potent immune-engaging formats.

A high-signal RNAi platform deal combining Alnylam's siRNA leadership with Inceptive's AI-native RNA design engine. The structure fits the broader 2026 theme of pharma and RNA leaders paying for AI-enabled discovery tools that could improve potency, durability, developability, or target throughput rather than only licensing named clinical assets.

A must-add genetic medicines deal: Lilly is extending its external-innovation push into RNA exon editing and kidney disease, an area already showing strong 2026 BD&L momentum. For Ascidian, the deal validates a differentiated RNA-editing approach that could avoid permanent DNA edits while potentially addressing large genes or mutation classes that are difficult for conventional gene editing.

A sizeable nephrology BD&L deal that gives Travere a potential next-wave rare kidney disease asset beyond FILSPARI while letting Everest monetize ex-Asia rights to a BTK inhibitor with best-in-class positioning claims. The structure fits the broader 2026 China-to-global template: meaningful upfront cash, large indication-based milestone stack, and Asia rights retained by the originator.

Another high-signal China-to-global BD&L transaction from Lilly, following its broader 2026 run of external-innovation deals. The economics are heavily milestone-weighted, but the scale of the package shows Lilly continuing to use Chinese-origin discovery as a source of multi-program pipeline optionality across therapeutic areas.

A focused rare-hematology pipeline bolt-on for Agios that adds an oral SYK inhibitor in ITP while keeping near-term economics relatively disciplined. The Phase 2 data were not a clean statistical win, but Agios is underwriting durable platelet-response signals and specialist commercial fit rather than a broad-market immunology opportunity.

A strategically interesting expansion of Lilly's GLP franchise beyond obesity and diabetes into GI / intestinal-failure biology. The asset is a long-acting GLP-2 analog in Phase 2 for short bowel syndrome, where Hanmi is positioning potential lower treatment burden versus daily GLP-2 therapy; for Lilly, the deal adds a rare-disease/GI shot on goal with modest upfront risk but meaningful milestone torque.

A major ASCO-week China-to-global oncology collaboration and one of 2026's largest BD&L packages. Pfizer is effectively buying a broad option set across ADCs and multi-specific antibodies while Innovent monetizes its discovery engine with a large upfront, milestone torque, royalties, and selective co-commercialization economics — reinforcing that Western pharma continues to pay premium strategic prices for China-origin oncology innovation despite the live regulatory/political overhang around China-sourced biotech structures.

A meaningful commercial-stage regional out-license that lets Hansa monetize European/MENA rights while concentrating capital and execution on the U.S. opportunity ahead of a potential approval decision. The deal also shows specialist pharma appetite for transplant/rare immunology assets with established but still underpenetrated commercial footprints.

A high-signal platform deal that blends Regeneron's antibody engine with Parabilis' Helicon peptide technology to create antibody-Helicon conjugates. The investor read-through is that intracellular-target delivery remains one of the hottest BD bottlenecks: pharma will pay platform-scale economics where conjugation or cell-penetrant technology could unlock historically inaccessible biology.

A smaller but relevant platform-validation deal. The key read-through is not the upfront — undisclosed and subject to definitive agreement — but that targeted oligonucleotide delivery remains partnerable, especially where antibody-based tissue targeting could solve delivery bottlenecks for genetic-medicine or conjugated-oligo approaches.

Not a therapeutic asset license, but a relevant pharma-BD datapoint because it shows agentic AI moving from pilots into enterprise licensing. The read-through is that pharma is starting to pay for AI systems embedded into R&D and competitive-intelligence decision workflows, not just discovery-stage target or molecule generation.

A late-stage CNS option deal with meaningful cash economics ahead of a pivotal Alzheimer's readout. The structure gives Fosun global optionality without fully committing before POLARIS-AD reads out, while AriBio brings in non-dilutive capital and preserves upside if Phase 3 data are positive.

One of the largest disclosed BD&L packages of 2026. BMS is using a broad, risk-sharing portfolio structure to access Hengrui's early innovation engine across three priority disease areas, rather than betting on a single named late-stage asset.

A notable late-stage oncology handoff: Arvinas and Pfizer monetize and de-risk VEPPANU while preserving meaningful royalties, while Rigel gets a near-commercial breast cancer asset that could materially reshape its revenue profile if uptake follows the ESR1-mutant opportunity.

A clean early immunology license reinforcing the continued bid for preclinical antibody assets when the biology is differentiated. For Immunitas, it provides non-dilutive validation and economics while shifting global development risk to a large immunology-focused pharma buyer.

A useful platform read-through for oncology drug delivery: this is Halozyme's first ENHANZE deal explicitly including ADC targets, suggesting large pharma is looking for formulation and convenience advantages even in complex oncology modalities.

Another validation point for the "less frequent, lower-burden biologics" thesis in immunology: Oruka's clinical story is already about durable disease control, and delivery technology could become part of the product-profile differentiation.

A clean China-to-West oligonucleotide deal in cardiometabolic disease — and not a me-too GLP-1 story. The ALK7 angle gives GSK a differentiated route into obesity-adjacent metabolic risk, with a structure that preserves SiranBio's Greater China optionality while handing global scale-up to pharma.

Strategically logical bolt-on for Madrigal: adds a genetically defined RNAi program to the MASH leader's pipeline and gives Arrowhead non-dilutive economics while keeping the program in the hands of a hepatology-focused commercial owner.

A meaningful pipeline-broadening move for Cue into allergic disease, with ex-Greater China rights to a Phase 2 dual-mechanism anti-IgE. The $15M upfront against $676.5M in milestones (~45x ratio) is also a useful data point on how far back-ended deals around mid-stage Chinese assets have become.

A rights-consolidation deal rather than a fresh discovery bet: Biogen pays to simplify global ownership of felzartamab as it builds around immunology and plasma-cell biology. The $100M upfront for a regional carve-out is also another useful marker for how much strategic buyers will pay to remove territorial friction around priority assets.

A tidy regional monetisation for a chronic HBV program: Aligos brings in non-dilutive capital while keeping the higher-value Western and Japan/South Korea rights. Also shows that China regional partners remain willing to fund development around antiviral assets, not just oncology or immunology programs.

Another example of AbbVie paying for ex-China optionality in pain and neuroscience. The portfolio-style structure is notable — broader ex-China read-through beyond a single named program, which widens Haisco's global partnering signal.

Useful validation that large-cap pharma still sees targeted protein degradation as a platform worth expanding into. The modest upfront but very large back-end also fits the current risk-sharing template for platform collaborations.

A smaller regional obesity deal, but useful as another sign that China-origin incretin assets are being monetized outside China beyond the headline mega-deals. The economics are modest, but South Korea rights for a differentiated long-acting GLP-1 add another datapoint for regional commercial appetite in obesity/metabolic disease.

Not a fresh asset license, but a meaningful amendment to a major CNS collaboration. The read-through is that Lilly is still willing to fund tau-pathway optionality alongside amyloid and broader neurodegeneration work, while AC Immune receives near-term non-dilutive cash and keeps exposure to a large milestone/royalty stack.

A clean read-through that Biogen is still willing to pay for enabling nucleic-acid platforms, not just named assets — useful context for how CNS-heavy buyers are sourcing next-wave genetic medicines optionality.

Smart regional monetisation around a mutation-defined oncology program: Frontier keeps Greater China while offloading ex-China development spend to a strategic partner, preserving upside if the p53 Y220C thesis translates clinically.

Another sizeable platform-driven antibody discovery pact, reinforcing that big pharma is still willing to pay meaningful downstream economics for differentiated target-to-antibody engines even before named clinical assets emerge.

Repeat-business validation for Insilico's AI platform from one of the most aggressive pharma buyers in external innovation. The size of the package suggests Lilly sees AI not just as a workflow tool, but as a scalable source of licensable oral assets.

Another sizeable immunology deal for a differentiated multispecific, showing that large buyers will still pay meaningful upfronts for early but mechanistically distinct autoimmune assets.

A classic "big pharma exits, specialist commercial player takes over" transaction, with real cash for a late-stage hepatology asset close to the regulatory finish line.

One of the most significant March BD&L deals: a China-origin commercial asset with a full global rights transfer and no Greater China carve-out. A strategic fit for Sanofi's transplant franchise alongside Rezurock.

Another "China-origin immune engager to global pharma" deal, but in autoimmune disease rather than oncology, with meaningful upfront economics for a differentiated masked/B-cell depletion concept.

One more datapoint that buyers still want differentiated oral immunology mechanisms, even at preclinical stage, if the biology looks first-in-class enough.

Another China-origin oligo deal with real though not giant upfronts — and a sign GSK wants more immunology and kidney shots via RNAi.

A large-ticket oncology deal around a masked T-cell engager with real cost-sharing and U.S. economics retention — not just a simple regional out-license. A strong signal that differentiated TCEs can still command major strategic capital.

Another big-pharma bet on macrocycles as a route to hard-to-drug targets, this time in cardiovascular rather than the usual oncology-heavy mix.

A neat rights-split around a late-stage IL-6 asset: CSL keeps the core renal-cardiovascular angle while Lilly gets optionality to widen the label.

Big milestone torque on a platform-originated MASH expansion — another "China RNAi → global build" template with a meaningful upfront, and a logical portfolio-broadening move for the MASH commercial leader.

Another "ADC platform option → exercise" datapoint — validates AraLinQ and keeps Japan-based buyers active in next-gen ADC technology.

A clean "explore → option-to-license" structure in a resurging modality (recombinant polyclonal IgG) with CSL as a natural strategic buyer.

Another "AI platform + big-pharma pipeline" deal with real headline economics — good sentiment marker for AI-enabled BD&L.

Another "China discovery + global scale" template — big upfront with milestone torque, and a clear division of labour through Phase 2 in China before ex-Greater China execution by Lilly.

A "Japan commercial + local MAH" structure for a de-risked IO asset — modest milestones but attractive royalty profile if uptake lands.

Early "molecular glue" exposure in a clear unmet-need niche (TKI-resistant GIST). Royalty callout suggests meaningful ex-Japan economic participation despite compact economics disclosure.

Roche/Genentech keeps leaning back into RNA — big upfront for an undisclosed program implies conviction in platform chemistry and delivery, with the classic "biotech does early, pharma scales" handoff.

Modest headline value but immediate non-dilutive cash and full global responsibility shift to the partner — if the PDE4 tolerability story holds, the royalty participation has meaningful optionality.

A sizeable early-2026 autoimmune platform deal that combines Sanofi's immunology appetite with Earendil's AI-enabled bispecific discovery engine. The economics are heavily back-ended, but the large upfront / near-term payment package makes it one of the more material discovery-stage BD&L transactions at the start of the year.

A useful obesity BD&L datapoint beyond injectables: Lilly is still adding external shots on goal around oral metabolic mechanisms despite already leading the incretin market. The structure is classic discovery-stage risk sharing — modest near-term cash relative to a large milestone stack.

Another China-to-global oncology license around a checkpoint bispecific, and a useful comparator to AbbVie's larger RemeGen PD-1/VEGF deal later in January. It reinforces AbbVie's 2026 appetite for China-origin IO assets with differentiated bispecific biology.

One of the biggest obesity BD packages yet — big upfront and portfolio scope signals "speed + breadth" over single-asset risk. Keeps China rights local while AZ builds global obesity footprint.

A clean "partner commercialisation" structure — Moderna keeps platform focus and de-risks go-to-market, while Recordati expands its rare disease franchise with a late-stage mRNA shot on goal.

Another China-to-West pipeline build: oral immunology differentiation (miR-124 axis) + Formation's "asset-in-Kenmare" structure suggests fast execution toward first-in-human while keeping economics milestone-weighted.

Clear appetite for "immune decoding → precision tolerance" rather than broad immunosuppression. Milestones-heavy economics fit discovery risk while keeping meaningful upside if Lilly's immunology machine delivers.

Yet another bet that next-gen editing beyond standard nuclease paradigms can deliver safer, more precise in vivo outcomes. Lilly is clearly stacking genetic medicine options in hearing and beyond.

AI discovery keeps getting "real money" partner validation — but the structure (milestones + royalties, no disclosed upfront) is a reminder that proof still comes in the clinic.

TL1A is already a crowded hot axis — pairing TL1A with IL-23p19 is a swing at higher efficacy. Meaningful preclinical upfront suggests Boehringer wants a differentiated shot versus mono-pathway competitors.

Classic "platform + antigen" bet: BMS takes the expensive late-stage risk after IND, while Janux keeps upside via milestones and royalties — structure reflects early-stage uncertainty but strong strategic validation.

Rare big-pharma validation of an external adjuvant platform: non-exclusive structure and supply obligation keep Pfizer flexible while giving Novavax recurring upside if Pfizer ships products with Matrix-M.

Clean regional commercialisation expansion: Eisai gets a near-commercial oncology asset for its footprint, while Nuvation keeps U.S. upside — structure signals "execution + geography" rather than core R&D risk.

A non-standard but economically large oncology licensing structure around a Phase 3-ready oral immunotherapy. It is less clean than a big-pharma license, but worth tracking because the proposed headline economics are large relative to OSR/Vaximm and highlight ongoing appetite for structured, finance-led licensing routes around late-stage oncology assets.

Another major "China-to-global" land grab in PD-1/VEGF — big upfront signals confidence and creates optionality for AbbVie combo regimens (especially with ADCs) while keeping Greater China with the originator.

AD BD is shifting from "just antibodies" to delivery and biology differentiation — shuttle tech is the real kicker here. Milestones-heavy economics fit early risk while keeping Novartis in the driver's seat globally.